Andrew Roberts Blog | Talkmarkets | Page 1
Healthcare Equity Analyst

I am a New Orleans native currently residing in Baton Rouge. My academic background is in actuarial sciences and financial mathematics. I've worked for the Louisiana Biomedical Research Network for the past four years and as Research Administrator of Healthcare for the United Traders group ... more

All Contributions

Latest Posts
1 to 2 of 2 Posts
Cerus Faces Pipeline Of Calamities Going Into 2021
In spite of common misconception, Cerus is not among the few companies to profit in treatment or prevention of the COVID-19 virus.
E Corcept Therapeutics: Discounted Biotech Company Offers Exceptional Risk Profile And Lucrative Proprietary Pipeline
Corcept is a rare low-risk/high-reward investment opportunity in the Biotechnology industry. Total 2018 revenues of $250-270 million represent 90% CAGR over the past 5 years. DCF and comp analysis indicate shares are currently discounted by 35%.
1 to 2 of 2 Posts